Scancell Holdings Share News (SCLP)

Hygea VCT Net Asset Value Drops In Half-Year As Scancell Shares Slide

Scancell Signs SCIB1 Vaccine Manufacturing Deal With Eurogentec

Scancell granted product licence extension from Ichor Medical Systems

(ShareCast News) - Scancell, the developer of immunotherapies for cancer treatments, was granted a product licence option extension from Ichor Medical Systems. The extension is to licence the commercial use of Ichor's TriGrid electroporation delivery system with SCIB1, Scancell's ImmunoBody vaccine,

Scancell Licence To Use TriGrid Technology Extended To 2018 (ALLISS)

Scancell Says Review Supporting Potential Of Moditope Published

Scancell Holdings SCIB1 Cancer Drug Shows "Compelling" Survival Data

Scancell suspends dosing with current supplies of SCIB1 for melanoma

(ShareCast News) - Shares in drug developer Scancell Holdings plunged almost 17% after it suspending dosing with current clinical trial supplies of SCIB1 for melanoma with immediate effect. Patients would be notified as soon as possible. AIM-quoted Scancell said quality-control analysis showed the

WINNERS & LOSERS SUMMARY: National Grid Hit By Break-Up Recommendation

UPDATE 1-Scancell slumps as drug problem disrupts melanoma trial

(Adds latest shares, details) LONDON, June 17 (Reuters) - British drug developer Scancell has suspended dosing in a cancer clinical trial because of quality problems with an immunotherapy treatment, wiping more than a quarter off the value of its shares on Friday. The company said te

BUZZ-Scancell: drug problem spurs worst day in 3 yrs

** Drug developer Scancell's shares down 27 pct, worst day in nearly three years, after suspends dosing in a cancer clinical trial because of quality problems with its immunotherapy treatment SCIB1 ** Co says current supplies of drug no longer meet original specification and are no longer s

Drug problem forces Scancell to suspend cancer trial dosing

LONDON, June 17 (Reuters) - British drug developer Scancell said on Friday it was suspending dosing in a cancer clinical trial because of quality problems with its immunotherapy treatment SCIB1. The company said tests showed the product, which is being assessed for melanoma, was "no longer

Scancell Holdings Suspends Dosing In SCIB1 Cancer Treatment Trials

Scancell's ImmunoBody Platform Chosen For Preclinical Glioma Study

CORRECT (18/05): Scancell Shuffles Board As New US Offices Open

BROKER RATINGS SUMMARY: Goldman Upgrades Booker, Panmure Cuts Meggitt